Verici Dx Share Discussion Threads

[wan] 03/10/2023 12:41

I have submitted a number of questions for the Presentation meeting on Thursday.

[wan] 03/10/2023 12:20

As indicated further above, I am at a pivotal point in terms of staying invested in Verici.

Food for thought: Verici has experienced a wide range of delays compared to most of their guidance, which has shaken investor confidence in relying on current and future guidance.

Given that apparently the house broker has forecast the closing net cash position at December 2023 of $0.8m, but with Verici maintaining current guidance of a cash runway until mid-2024 as coming from higher than expected research related revenues, one would assume that such additional revenues, given the indicated overheads/spending, to be in the order of at least $5m, so one could assume that there must be a better than reasonable chance of contract announcements to follow.

Time will tell, but patient investors are surely due something tangible and more reliable.

[brummy_git] 29/9/2023 08:47

Terrific progress being made on the R&D front from Verici Dx.

Albeit initial adoption of its state-of-the-art kidney transplant test (Tutivia) appears to be taking longer than originally anticipated.

All the details here.

[wan] 29/9/2023 08:13

The Presentation meeting next week, including the Q&A (and any announcements that we might get in between) will be pivotal to my continued interest and investment in Verici.

[oapknob1] 29/9/2023 08:10

Poor sales. Lower than projected and slower progress. More patience then

[wan] 28/9/2023 11:12

OAP...Well, the situation is firmly on my radar.

I am still of the opinion that Verici must surely be in the sights of potential partners given the changing backdrop to transplant testing in the US.

Tutivia is unique and has key advantages over the other tests on the market, and likewise for the upcoming test, Clarava. Combined, I would go as far as suggesting that those two tests could disrupt the current state of transplant testing. Time will tell!

But don't forget that I also highlighted from the MolDx updates re test coverage etc that combining both types of tests may further improve graft rejection determination, e.g. donor-derived cell-free deoxyribonucleic acid tests (cfDNA - from the likes of CareDx and Natera) and gene expression profile tests (GEP - from the likes of Verici).

[oapknob1] 27/9/2023 22:11

What's your thoughts on a lack of update or Half year report ?

[wan] 27/9/2023 13:46

I note Verici's Tutivia web pages were recently updated, presumably to align with the commercial roll out -

I also note the following -

National Kidney Foundation: New Organ Procurement Transplant Law Is Game Changer
By Kevin Longino -
September 26, 2023

The Securing US Organ Procurement and Transplantation Network (OPTN) Act will help improve the transplant system by promoting innovation, transparency, and accountability across the system. It will improve equity and access to transplantation for all Americans. Modernize the technology that matches donors to recipients and create a more efficient system to maximize the number of organs that can be transplanted.

[oapknob1] 18/9/2023 08:03

No sign of a Half year yet

[oapknob1] 05/9/2023 15:11

Expecting bad news with all the selling ?

[wan] 18/8/2023 10:44

Keeping firmly in mind Verici's clear product differentiation and competitive advantages, and how close Verici is in terms of launching their second test, Clarava, I would particularly highlight the following -

3rd July 2023
The Clarava(TM) study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava(TM) demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava(TM) as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava(TM) in conjunction with our post-transplant test, Tutivia(TM).
(END)

As previously highlighted on here, due to the local coverage changes, limiting testing to only one molecular test for a given patient encounter, I mentioned that Clarava could set up Tutivia (and other molecular tests) for additional testing.

I have been digesting 'another' iteration from MolDX, who recently opened a public comment period for proposed changes on a draft local coverage decision for solid organ transplant molecular testing.

Again, keeping the paragraph regarding Clarava (further above) firmly in mind, demonstrating statistically significant results identifying high-risk and low-risk patient groups in terms of organ rejection (a pre-test), and how such a pre-test might facilitate the approval/need for additional testing, and how in 'certain scenario's' MolDX recognises the value of 'additional' surveillance testing. And then consider how the following excepts from the MolDX proposed changes could, and already has, disrupted the current regime of kidney transplant testing -

Scroll down to the paragraph starting "In all scenarios presented" and read the next seven paragraphs -

Full MolDX release -
Updated on 08/08/2023
Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection


My interpretation is that those excerpts describe a pre-test, such as Clarava, that enables/satisfies the criteria for additional testing for the likes of Tutivia (itself differentiated compared to existing tests) and would therefore be in compliance with such policy.

Coverage of the recent MolDX Public Comment Period is covered here, including comment from CareDX who are clearly rattled -
Public Comment Period Opened for Draft LCD on Solid Organ Transplant Molecular Testing
Aug 11, 2023


It's as if MolDx can see the future of transplant testing, and the future of transplant testing is Verici!

In my view, the potential for strategic news flow appears to be increasingly weighted to the positive side of the scales. Time will tell!

[adorling] 17/8/2023 22:37

Takeover target for sure…. So under the radar

[oapknob1] 07/8/2023 08:33

Is it October for CMS to confirm the Clinical Laboratory Fee Schedule or sooner ?

[mrmarmalade] 28/7/2023 20:25

wan...really insightful thanks for your (continued) research. Keeping this thread up to speed. BW MM

[wan] 28/7/2023 09:00

And just to be clear, according to Verici, Tutivia can provide information on not only one, but all three of the required MolDX clinical status determinations.

[wan] 20/7/2023 09:18

Recall from the FY Results that Verici is also looking to extend and broaden their revenue streams this year, which could include potential collaborations with pharmaceutical and medtech/data companies that could benefit from the application of the Company's transcriptomic analysis technology in different settings.

Clearly Pharma and medtech companies are very interested in biomarkers with high sensitivity and specificity that can effectively evaluate diagnosis, monitor treatment response and prognosis, and ultimately, where needed, assist clinicians in making timely therapeutic intervention. That's a big win in terms of organ utilisation (and not just for kidneys'), a reduction in transplant waiting lists, and the long-term, sustainable outcome for transplant patients.

Such collaborations would likely be catalytic in terms of enhancing Verici's prospects, its cash flow and net cash position, and indeed the same would apply with regard to Verici's share price!

[oapknob1] 20/7/2023 08:39

Looking forward to this update when it lands.Proposed US pricing for Tutivia(TM)Medicare proposed gapfill median rate of $2,650 per test.This proposed rate is currently open for public comment before it is finalised later this year. Following finalisation, the price in the CLFS is valid for a period of three years from 1 January 2024, after which it is subject to further review.

[oapknob1] 20/7/2023 08:36

It's sales and revenue that's needed.

[wan] 20/7/2023 07:56

With the expansion of Verici's commercial reach, positive progress continues to be made. I am expecting that we will see the continued release of further positive news flow.

[brummy_git] 20/7/2023 07:56

Another major milestone ticked off today by next generation immuno-diagnostics firm Verici Dx (ie for kidney transplant patients)

All the details here.

[oapknob1] 20/7/2023 07:24

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that further to the RNS dated 2 March 2023 , the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California , with the Company laboratory now fully accredited in a total of 49 states.

[wan] 12/7/2023 09:03

A good presentation yesterday (I could not make the live presentation), highlighting the strategy and the expected milestones etc for the remainder of this year and into 2024.

I was interested to learn of what Verici called their 'fourth test', as a research asset for use in the research space, which is likely to be used in a collaboration.

In answer to a question regarding interest from strategic partners (not a question from me), we got confirmation that Verici talks with everyone in the transplant space and that 'there is a lot of interest in multiple ways'.

So, no reason to change my view that the next few months will deliver various items of important news flow, and I would not discount that including strategic collaborations/corporate activity that enables/aligns with a major inflection point (commercial ramp) in early 2024.

[sharw] 06/7/2023 15:41

Shares from EKF dividend in specie credited to my ii a/c today. Did a dummy sell and was quoted 12.181p/share.

Also hold elsewhere and not yet available.